Journal of Epidemiology and Public Health

Prevalence of Virologic Failures in Adult Patients Receiving Are Treatment at Sikasso Hospital

Abstract

Konate Cheickna, Almoustapha I Maiga, Daouda K Minta, Souleymane Diallo and Oumar Kassogue

IntroductionThe Human Immunodeficiency Virus (HIV) is the etiological agent of Acquired Immunodeficiency Syndrome (AIDS). Virologic failure is defined as the persistence of a viral load greater than or equal to 1000 copies based on 2 consecutive viral loads 3 months apart, after 6 months of well-conducted treatment. The aim of our study was to estimate the prevalence of virological failures in adult patients on ARV treatment at Sikasso Hospital.

Material and methods: This was a 12-month prospective descriptive study from January to December 2016 on adult HIV-1 patients on ARVs at least one (1) year of age who had previously had a plasma viral load in the laboratory department of Sikasso hospital. Viral loads were performed by real-time RT-PCR on Abbott M2000rt with a detection limit of 40 copies/mL.

Results: We conducted a study on 319 patients, 46.4% of whom were from CERKES, followed by Sikasso Hospital with 33.3%. The prevalence of failure was 27.8% at one year, 19.5% at two years, 12% at three years, and 19.4% at more than three years of antiretroviral treatment. The frequency of undetectable viral load was 57.4% at one year, 74.4% at two years, 84% at three years, and 63% at more than three. Among the patients under Trioday (TDF + 3TC + EFV) the prevalence of virologic failure was 19.5%. In patients taking Duovir-N (AZT + 3TC + NVP) the prevalence of virologic failure was 20.7%. No virological failure has been observed in Tenolam + Kaletra patients (TDF + 3TC + LPV / r). Among patients taking Duovir + Kaletra (AZT + 3TC + LPV / r) the prevalence of virologic failure was 28.7%.

Conclusion: The proportion of virological failures decreases with increasing duration of ARV treatment.

PDF